Intervention Review

Azathioprine for multiple sclerosis

  1. Ilaria Casetta1,*,
  2. Gerardo Iuliano2,
  3. Graziella Filippini3

Editorial Group: Cochrane Multiple Sclerosis Group

Published Online: 17 OCT 2007

Assessed as up-to-date: 24 MAY 2007

DOI: 10.1002/14651858.CD003982.pub2

How to Cite

Casetta I, Iuliano G, Filippini G. Azathioprine for multiple sclerosis. Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No.: CD003982. DOI: 10.1002/14651858.CD003982.pub2.

Author Information

  1. 1

    Universita degli Studi di Ferrara, Sezione di Clinica Neurologica; Dip.to di Discipline Medico Chirurgiche della Comunicazione e del Comportamento, Ferrara, Italy

  2. 2

    Ospedali Riuniti di Salerno, U.O. Neurologia, Salerno, Italy

  3. 3

    Fondazione I.R.C.C.S. - Istituto Neurologico C.Besta, Neuroepidemiology Unit, Milano, Italy

*Ilaria Casetta, Sezione di Clinica Neurologica; Dip.to di Discipline Medico Chirurgiche della Comunicazione e del Comportamento, Universita degli Studi di Ferrara, Corso della Giovecca, 203, Ferrara, 44100, Italy. cti@unife.it.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 17 OCT 2007

SEARCH

Cited in:

CrossRef

This article has been cited by:

  1. 1
    N. Melzer, S. G. Meuth, Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies, Clinical & Experimental Immunology, 2014, 175, 3
  2. 2
    Sofia Fernanda Gonçalves Zorzella-Pezavento, Fernanda Chiuso-Minicucci, Thais Graziela Donegá França, Larissa Lumi Watanabe Ishikawa, Larissa Camargo da Rosa, Priscila Maria Colavite, Camila Marques, Maura Rosane Valerio Ikoma, Célio Lopes Silva, Alexandrina Sartori, Downmodulation of peripheral MOG-specific immunity by pVAXhsp65 treatment during EAE does not reach the CNS, Journal of Neuroimmunology, 2014, 268, 1-2, 35

    CrossRef

  3. 3
    Darin T. Okuda, Multiple Sclerosis and Related Disorders, 2014,

    CrossRef

  4. 4
    A. García-Merino, Ó. Fernández, X. Montalbán, C. de Andrés, C. Oreja-Guevara, A. Rodríguez-Antigüedad, T. Arbizu, Consensus statement on medication use in multiple sclerosis by the Spanish Society of Neurology's study group for demyelinating diseases, Neurología (English Edition), 2013, 28, 6, 375

    CrossRef

  5. 5
    John Zajicek, Neurological Rehabilitation, 2013,

    CrossRef

  6. 6
    A. García Merino, O. Fernández, X. Montalbán, C. de Andrés, T. Arbizu, Spanish Neurology Society consensus document on the use of drugs in multiple sclerosis: Escalating therapy, Neurología (English Edition), 2010, 25, 6, 378

    CrossRef

  7. 7
    Tamir Ben-Hur, MULTIPLE SCLEROSIS 3, 2010,

    CrossRef

  8. 8
    Thomas Berger, Current therapeutic recommendations in multiple sclerosis, Journal of the Neurological Sciences, 2009, 287, S37

    CrossRef

  9. 9
    Benjamin M. Greenberg, John N. Ratchford, Peter A. Calabresi, Pharmacology and Therapeutics, 2009,

    CrossRef

  10. 10
    Georg Pilz, Peter Wipfler, Gunther Ladurner, Jörg Kraus, Modern multiple sclerosis treatment – what is approved, what is on the horizon, Drug Discovery Today, 2008, 13, 23-24, 1013

    CrossRef

  11. 11
    Graziella Filippini, Cinzia Del Giovane, Laura Vacchi, Roberto D'Amico, Carlo Di Pietrantonj, Deirdre Beecher, Georgia Salanti, Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis, The Cochrane Library,